Altasciences Partners with Metsera for Early-Stage Obesity Clinical Trials
Altasciences is pleased to have supported Metsera, Inc., a clinical-stage biopharmaceutical company focused on advancing next-generation treatments for obesity and metabolic diseases, in its nonclinical and early-stage clinical trials. This…
NorthStar and Cellectar Partner on Actinium-225 Supply Agreement
NorthStar Medical Radioisotopes, LLC, a leader in radiopharmaceutical innovation, has entered into a strategic Master Supply Agreement with Cellectar Biosciences, Inc. (NASDAQ: CLRB). Under the agreement, Cellectar will integrate NorthStar’s…
Institut Curie Adopts Ibex Medical Analytics AI Tools to Advance Cancer Diagnostics
Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, has announced the integration of its advanced AI solutions into routine clinical practice at Institut Curie, one of the world’s…
Trinity Life Sciences Advocates Transformative Approach to Evaluating Field Medical Affairs Impact
Trinity Life Sciences, a leader in strategy, insights, and analytics for the life sciences industry, has introduced a groundbreaking approach to evaluating the impact of Field Medical Affairs in its…
Omeros Corporation Shares Update on BLA Resubmission Progress
Omeros Corporation (Nasdaq: OMER) has shared an update on its ongoing efforts to resubmit the biologics license application (BLA) for narsoplimab, its first-in-class antibody targeting MASP-2, a key enzyme in…
Pfizer Appoints New Chief Scientific Officer and President of R&D
Pfizer Inc. (NYSE: PFE) has announced the appointment of Chris Boshoff, M.D., PhD, as its new Chief Scientific Officer and President of Research & Development, effective January 1, 2025. Dr.…
EU Approves Pfizer’s HYMPAVZI™ for Severe Hemophilia A/B in Adults and Adolescents
Pfizer Inc. (NYSE: PFE) has received marketing authorization from the European Commission (EC) for HYMPAVZI™ (marstacimab) for the routine prevention of bleeding episodes in patients aged 12 years and older,…
Tasfygo® Tablets 35mg Launched in Japan for FGFR2-Positive Biliary Tract Cancer
Eisai Co., Ltd. has announced the launch of TASFYGO® Tablets 35mg (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer harboring FGFR2 gene…
Bio-Techne Signs Distribution Agreement with Leader Life Sciences
Bio-Techne Corporation (NASDAQ: TECH), a leading global provider of innovative tools and bioactive reagents for research and clinical diagnostics, has announced a strategic partnership with Leader Life Sciences. Under this…
Improving Access to Pediatric Medicines on World Children’s Day
On World Children’s Day, the Global Accelerator for Paediatric Formulations Network (GAP-f) highlighted the urgent need for better access to essential medicines for children, particularly in low-resource settings. Despite their…
Local Climate Action, Global Health Benefits
On Wednesday, November 20, the UN Climate Conference (COP29) in Baku, Azerbaijan, spotlighted urbanization and transportation as critical areas for climate action. The day emphasized the pivotal role of cities…
Jazz Pharma Gains FDA Approval for Ziihera® to Treat Advanced HER2+ Biliary Tract Cancer
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Ziihera® (zanidatamab-hrii) 50mg/mL injection. This intravenous treatment is for adults with previously…